Phase 2 Start~month

Phase 2 Start: A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular

Indication
Relapsed or Refractory Multiple Myeloma

Other upcoming events for AZN

Phase 1 StartPhase 1 Start: A Phase I, Randomized, Single-blind, Placebo-controlled, 2-Part Study to Assess the Safety, Tolerabi
Phase 2 StartPhase 2 Start: A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Sa
Phase 1 StartPhase 1 Start: An Open-label, Randomised, Two Arm, Fixed Sequence Study in Healthy Participants to Assess the Pharm
Phase 3 ReadoutPhase 3 Topline: A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive
Phase 3 ReadoutPhase 3 Topline: A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 2 Start: A Modular, Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, Cellular — AZN Phase 2 Start | BioSniper